Publications by authors named "Gail Bukofzer"

Claim this Profile
A
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Adam S Chervin, Jennifer D Stone, Iwona Konieczna, Kelly M Calabrese, Ningyan Wang, Gail T Bukofzer

Mol Cancer Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
Jun Guo, Yu Xiao, Ramesh Iyer, Xin Lu, Marc Lake, Gail Bukofzer

PLoS One· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.
Philip D Bardwell, Matthew M Staron, Junjian Liu, Qingfeng Tao, Susanne Scesney, Gail Bukofzer

Protein Cell· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Sarah R Mudd, Kimberley D Holich, Martin J Voorbach, Todd B Cole, David R Reuter, Gail Bukofzer

Mol Imaging Biol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Thomas D Penning, Gui-Dong Zhu, Jianchun Gong, Sheela Thomas, Viraj B Gandhi, Gail T Bukofzer

J Med Chem· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Joann P Palma, Yi-Chun Wang, Luis E Rodriguez, Debra Montgomery, Paul A Ellis, Gail Bukofzer

Clin Cancer Res· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer

Anticancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Robin R Frey, Michael L Curtin, Daniel H Albert, Keith B Glaser, Lori J Pease, Gail Bukofzer

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor.
Jieyi Wang, Lora A Tucker, Jason Stavropoulos, Qian Zhang, Yi-Chun Wang, Gail Bukofzer

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Daniel H Albert, Paul Tapang, Terrance J Magoc, Lori J Pease, David R Reuter, Gail T Bukofzer

Mol Cancer Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae.
W Edward Swords, Miranda L Moore, Luciana Godzicki, Gail Bukofzer, Michael J Mitten

Infect Immun· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis